Kodu・Aktsiate loetelu・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Suletud

SektorTervishoid

13.14 -2.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.92

Max

13.45

Põhinäitajad
By Trading Economics
Sissetulek	-1.2M -13M
Müük	-2.8M 14M
Aktsiakasum	-0.67
Kasumimarginaal	-76.292
Töötajad	120
EBITDA	-30M -39M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+48.81% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	13. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-22M 400M
Eelmine avamishind	15.59
Eelmine sulgemishind	13.14

Uudiste sentiment

By Acuity

75%

25%

317 / 340 Pingereas Healthcare

ENANTA PHARMACEUTICALS INC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. aug 2026, 20:06 UTC

Enanta Pharmaceuticals is trading lower amid mixed market sentiment following a reported decline in U.S. retail sales for July.

13. aug 2026, 19:36 UTC

Enanta Pharmaceuticals Inc is trading higher, remaining above its 20-day moving average, despite no specific company news identified for the price movement.

11. aug 2026, 20:06 UTC

Enanta Pharmaceuticals Inc shares are lower today, reflecting broader market declines. The stock reached a session low earlier but has since recovered slightly.

5. aug 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower, reflecting broader market sentiment amid disappointing ADP employment data showing a rise of only 44,000 jobs in July.

4. aug 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are higher, buoyed by a decline in crude oil prices that eases inflation concerns. No specific company news was identified.

3. aug 2026, 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31. juuli 2026, 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30. juuli 2026, 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29. juuli 2026, 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28. juuli 2026, 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27. juuli 2026, 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24. juuli 2026, 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21. juuli 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20. juuli 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Võrdlus sarnastega

Hinnamuutus

ENANTA PHARMACEUTICALS INC Prognoos

Hinnasiht

By TipRanks

48.81% tõus

12 kuu keskmine prognoos

Keskmine 20 USD 48.81%

Kõrge 20 USD

Madal 20 USD

Põhineb 1 Wall Streeti analüütiku instrumendi ENANTA PHARMACEUTICALS INC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi ENANTA PHARMACEUTICALS INC aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

317 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.